Hematology Frontier

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation, and hosted by the Beijing Lu Daopei Hematology Institute. The conference gathered world-leading hematology experts and focused on hematopoietic stem cell transplantation, cellular therapy, and precision treatment of hematologic malignancies. With over a thousand participants, the meeting provided a high-level and in-depth academic exchange. During the conference, Professor Fang Liu from Shanghai Xindaobei Hematology Hospital delivered a presentation on the latest clinical advances of CAR-T therapy in acute myeloid leukemia (AML). Oncology Frontier – Hematology News invited Professor Liu to elaborate on the core clinical issues, offering important insights to guide optimized management strategies.

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

On August 22–23, 2025, the 13th Lu Daopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

On August 22–23, 2025, the 13th Ludaopei Hematology Conference was grandly held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease…

Editor’s Note: As autumn scents the air with osmanthus blossoms, leading scientists gathered in Kumamoto for an intellectual feast. The 54th Annual Scientific Meeting of the International Society for Experimental…

The European Society for Medical Oncology (ESMO) Congress 2025 was grandly held in Berlin, marking another wave of scientific innovation across the field of oncology.In hematology, several exciting advances drew attention—from uncovering the mechanisms of CAR-T resistance and exploring dual-target immunotherapies, to studies on precision treatment discontinuation in multiple myeloma and single-cell immune atlas mapping that deepens our understanding of hematologic malignancies. Together, these studies highlight continuous innovation in medical science and bring new hope for improving diagnosis and treatment in hematologic diseases.To further focus on major breakthroughs in hematology and foster academic exchange, Oncology Frontier – Hematology News invited Dr. Sicong Zhang, from Professor Huilai Zhang’s research group at Tianjin Medical University Cancer Institute and Hospital, to discuss the innovation and clinical significance of a new study presented at ESMO 2025, as well as to share his insights into future trends in the field.

In hematology, this year’s highlights encompassed several cutting-edge research directions—from unraveling the mechanisms of CAR-T resistance and exploring dual-target immunotherapies that may enhance precision and efficacy, to studies on treatment-free remission in multiple myeloma, and the creation of single-cell immune atlases offering novel insights into hematologic disease mechanisms. These achievements collectively reflect the continued progress and innovation in biomedical science and bring new hope for patients with hematologic malignancies.

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan. As one of the most prestigious international conferences in the field of hematology, this year’s meeting gathered leading experts from around the world to engage in in-depth discussions on the latest advances in basic hematology, immunology, stem cell research, and cell and gene therapy. During the conference, Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Toshio Suda, former President of ISEH and Distinguished Professor at Peking Union Medical College, who shared his insights on the major highlights of the meeting and the latest developments in stem cell research.

Editor’s Note: The 21st International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) was held from September 12–15, 2025, in Kraków, Poland. As the premier global academic event dedicated to chronic…

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan, bringing together leading global experts in hematology to discuss cutting-edge advances in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the major highlights of the event was the Sino-Japanese Joint Symposium on Stem Cells and Cellular Therapy, which drew wide attention. At the symposium, Professor Fumio Arai from Kyushu University, Japan, delivered an insightful presentation titled “Signaling networks governing hematopoietic stem cell quiescence.” In this interview, Oncology Frontier – Hematology Frontier invited Professor Arai to discuss the role of signaling networks in maintaining stem cell function and their potential in clinical applications.